US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

41.65

+0.01000.02%

Post-market: 41.650.00000.00%19:59 EDT

Volume:230.10K

Turnover:9.56M

Market Cap:301.96M

PE:- -

High:42.04

Open:41.84

Low:41.25

Close:41.64

52wk High:42.97

52wk Low:23.90

Shares:7.25M

Float Shares:7.25M

Volume Ratio:0.80

T/O Rate:3.17%

Dividend:0.28

Dividend Rate:0.67%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Roche says Phase II obesity study met both primary endpoints

Moderna Inc. Stock Climbs 12.3%, Outperforms Peers

Moderna Provides Details on Data Presentations at Upcoming Conferences

MT Newswires Live

Twist Bioscience CEO Emily M. Leproust Disposes of USD 51.47 Million in Common Shares

Why Is Moderna Stock (MRNA) Soaring Today, September 21?

Moderna Inc Stock (MRNA) Moved Up by 14.21% on Sep 21: Drivers Behind the Movement

Moderna Stock Jumps. Its mRNA Cancer Vaccine is Getting Ready for Its Next Big Test.

Moderna to Present Late-Breaking Phase 3 Melanoma Data for Intismeran Autogene at ESMO 2026

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Moderna announces late-breaking data to be presented at ESMO Congress 2026

Avalyn Pharma announces published results from Phase 1 trials of AP02

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

Vertex Pharmaceuticals Incorporated : Leerink Partners Resumes Coverage with Outperform Rating; Target Price $594

THOMSON REUTERS

Ultragenyx price target raised to $35 from $32 at Barclays

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Amneal Pharmaceuticals (AMRX)

Incyte Expands Skin Diseases Treatment Partnership in Australia

MT Newswires Live

Correction to Vertex Material Listing Article on Sept. 17

Specialised Therapeutics expands partnership with Incyte to include Opzelura

Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/IDNA/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":41.65,"timestamp":1790971200000,"preClose":41.64,"halted":0,"volume":230097,"hourTrading":{"tag":"盘后","latestPrice":41.65,"preClose":41.65,"latestTime":"19:59 EDT","volume":3094,"amount":128861.28,"timestamp":1790985596008,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.00024015369836690706,"floatShares":7250000,"shares":7250000,"eps":0,"marketStatus":"Market Closed","change":0.01,"latestTime":"10-02 16:00:00 EDT","open":41.84,"high":42.04,"low":41.25,"amount":9561511.483608,"amplitude":0.018972,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":41.64,"sharesOutstanding":5100000,"nav":41.483661,"aum":309053274.45,"dividendRate":0.006706,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":41.8183,"preClose":41.64,"latestTime":"09:24 EDT","volume":122,"amount":5156.36538,"timestamp":1790947482007,"change":0.1783,"changeRate":0.004282,"amplitude":0.028206},"postHourTrading":{"tag":"盘后","latestPrice":41.65,"preClose":41.65,"latestTime":"19:59 EDT","volume":3094,"amount":128861.28,"timestamp":1790985596008,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8041356708242576,"impliedVol":0.1282,"impliedVolPercentile":0.243},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":7250000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.8041356708242576,"shares":7250000,"dividePrice":0.2793,"high":42.04,"amplitude":0.018972,"preClose":41.64,"low":41.25,"week52Low":23.9,"pbRate":"--","week52High":42.97,"institutionHeld":0,"latestPrice":41.65,"eps":0,"divideRate":0.006706,"volume":230097,"delay":0,"ttmEps":0,"open":41.84,"prevYearClose":26.19,"prevWeekClose":41.77,"prevMonthClose":42.32,"prevQuarterClose":42.32,"fiveDayClose":41.77,"twentyDayClose":40.29,"sixtyDayClose":34.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669414868","title":"Roche says Phase II obesity study met both primary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2669414868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669414868?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:20","pubTimestamp":1790068829,"startTime":"0","endTime":"0","summary":"Roch announced topline results from CT-388-104, a Phase II clinical trial evaluating enicepatide, an investigational, once-weekly dual GLP-1/GIP re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-says-phase-ii-obesity-study-met-both-primary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-says-phase-ii-obesity-study-met-both-primary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JDOC","IDNA","NVIB","HYLG","GDOC","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669619383","title":"Moderna Inc. Stock Climbs 12.3%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2669619383","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669619383?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:33","pubTimestamp":1790022780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. jumped 12.3% to $172.94 on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 2.3% to 27,122.09 and the Dow Jones Industrial Average rising 0.7% to 52,048.83.Moderna Inc. closed 2.1% short of its 52-week high of $176.66, which the company reached on August 19th.The stock outperformed some of its peers, as Johnson & Johnson fell 0.2% to $269.47, Pfizer Inc. rose 0.3% to $27.74, and Gilead Sciences Inc. rose 0.30% to $150.56.Trading volume totaled 20.9 million, compared to the 50-day average of 17.9 million.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","LU2468319806.SGD","WDNA","LU1778281490.HKD","LU0965509101.SGD","LU1066053197.SGD","IE0002270589.USD","IE00B7SZLL34.SGD","IBBQ","LU1023059063.AUD","BK4548","LU1066051498.USD","LU1430594728.SGD","BMED","IBB","LU1061106388.HKD","LU1839511570.USD","BK4533","LU0109394709.USD","BK4139","BK4532","BK4534","LU0234570918.USD","LU0859254822.USD","LU2089984988.USD","LU0320765992.SGD","LU0058720904.USD","MRNX","IDNA","IE00BSNM7G36.USD","LU1674673428.USD","BK4501","LU0889565916.HKD","SG9999015952.SGD","BK4578","MRNA","LU0122379950.USD","LU1934455194.USD","MRNY","SG9999015986.USD","GNOM","GILD","TMED","LU0861579265.USD","LGHT","LU0289739699.SGD","TBXU","BIB","BBH","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669619810","title":"Moderna Provides Details on Data Presentations at Upcoming Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2669619810","media":"MT Newswires Live","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669619810?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:13","pubTimestamp":1790021603,"startTime":"0","endTime":"0","summary":"Moderna  said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: 173.39, Change: +19.35, Percent Change: +12.56","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IDNA","LGHT","BK4532","BK4501","BK4588","WDNA","BK4551","MRNA","MRNX","BK4548","BK4568","BK4533","BK4585","GNOM","MRNY","BK4139","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669119897","title":"Twist Bioscience CEO Emily M. Leproust Disposes of USD 51.47 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2669119897","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669119897?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:06","pubTimestamp":1790021163,"startTime":"0","endTime":"0","summary":"Twist Bioscience CEO Emily M. Leproust disposes of USD 51.47 million in common sharesTwist Bioscience CEO Emily M. Leproust exercised employee stock options for 208,708 shares on Sept. 17, 2026.She so","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL6bV88H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Twist Bioscience CEO Emily M. Leproust Disposes of USD 51.47 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ARKG","IDNA","BK4139","WDNA","GNOM","BK4588","TWST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669160402","title":"Why Is Moderna Stock (MRNA) Soaring Today, September 21?","url":"https://stock-news.laohu8.com/highlight/detail?id=2669160402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669160402?lang=en_us&edition=fundamental","pubTime":"2026-09-22 02:54","pubTimestamp":1790016874,"startTime":"0","endTime":"0","summary":"Moderna shares ($MRNA) surged by more than 14% to about $176 on Monday afternoon. This came after the U.S. pharma and biotech firm announced a key ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-moderna-stock-mrna-soaring-today-september-12?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-moderna-stock-mrna-soaring-today-september-12?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4501","GNOM","BK4588","BK4548","MRNX","BK4585","BK4551","NVIB","BK4139","BK4568","LGHT","MRNY","BK4532","XBIX","WDNA","MRNA","BK4533","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669316058","title":"Moderna Inc Stock (MRNA) Moved Up by 14.21% on Sep 21: Drivers Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669316058","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669316058?lang=en_us&edition=fundamental","pubTime":"2026-09-22 02:15","pubTimestamp":1790014526,"startTime":"0","endTime":"0","summary":"• Moderna stock rose due to positive Phase 3 oncology trial results and upcoming congress presentations.\n• FDA approval of updated COVID-19 vaccines and capital-raising initiatives reinforced institutional financial confidence.\n• Moderna reported annual revenue of $1.94 billion and a net loss of $2.82 billion.","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262178943-market-movers-mrna-20260921","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4533","WDNA","BK4532","MRNX","BK4548","GNOM","MRNA","BK4139","BK4585","IDNA","BK4534","LGHT","BK4588","MRNY","BK4501","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669528167","title":"Moderna Stock Jumps. Its mRNA Cancer Vaccine is Getting Ready for Its Next Big Test.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669528167","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669528167?lang=en_us&edition=fundamental","pubTime":"2026-09-22 01:12","pubTimestamp":1790010720,"startTime":"0","endTime":"0","summary":"Moderna stock nearly tripled in a single day last month after the drugmaker proved a personalized cancer vaccine is no longer just theoretical. Investors are about to find out what's next.The drugmake","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4532","BK4501","BK4551","GNOM","BK4588","MRNY","BNTX","WDNA","BK4585","BK4568","LGHT","BK4534","IDNA","MRNA","BK4139","BK4548","BK4533","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669162946","title":"Moderna to Present Late-Breaking Phase 3 Melanoma Data for Intismeran Autogene at ESMO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669162946","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669162946?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:23","pubTimestamp":1790007833,"startTime":"0","endTime":"0","summary":"Moderna to present late-breaking Phase 3 melanoma data for intismeran autogene at ESMO 2026Moderna flagged three ESMO Congress 2026 presentations on intismeran autogene, an individualized mRNA neoanti","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL77ZC1z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MRNY","BK4533","BK4568","BK4534","BK4139","BK4501","LGHT","GNOM","MRNA","WDNA","MRNX","BK4548","BK4585","BK4532","BK4551","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669016473","title":"S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT","url":"https://stock-news.laohu8.com/highlight/detail?id=2669016473","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669016473?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:00","pubTimestamp":1790006406,"startTime":"0","endTime":"0","summary":"BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDTS&P 500.SPXTop PerformersPercent ChangeIntel CorpINTC.OQ+14.1%Akamai Technologies IncAKAM.OQ+11.3%Paramount Skydance CorpPSKY.OQ+","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL8N45D1L4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFSS7M15.SGD","LU0630314457.HKD","SPXL","BK4131","LU2360032135.SGD","INTW","LU1280957306.USD","SPUS","UPRO","XYLD","LU0256331488.USD","ETFT","UPSG","BK4122","LU2764263203.CNY","LU0868494708.USD","LU1074936037.SGD","VOO","BK4529","CHPS","BK4559","IE00B7SZLL34.SGD","LU2462591277.SGD","SUPL","LU2720916845.USD","LU2999663052.SGD","LU0149725797.USD","HPQ","LU0889566641.SGD","LU0942090050.USD","INTC","IE00BJJMRY28.SGD","LU0417517546.SGD","IE00B7KXQ091.USD","LU0097036916.USD","BK4548","LU0225771236.USD","LU0320765646.SGD","LU0477156953.USD","SPYD","IVV","LU1267930227.SGD","LU2543165471.USD","LU0072461881.USD","SPHD","LU0456854461.SGD","BK4534","LU0868494617.USD","OILT","VEU","IE00BGHQF524.EUR","RSPN","LU0742534661.SGD","LU2954938101.SGD","LU1988902786.USD","ONLN","SPUU","UPS","WEEI","IE000BZT7R73.USD","LU0143551892.USD","04335","DIG","MRNX","LEGR","LGHT","SPLV","BK4213","JEPI","VTV","LU0444973449.USD","LU0345781412.USD","LU1162221912.USD","LU0128525689.USD","ITOT","LU0061474960.USD","LU0976567544.SGD","IE0004445015.USD","LU0310799852.SGD","BK4532","BK4554","LU0162691827.USD","LU0310800965.SGD","LU1506573853.SGD","LU1623119135.USD","LU0266512127.USD","LU1585245621.USD","LU2764262908.HKD","MMAX","IE00B19Z3581.USD","BK4139","BK4533","FTXN","LU0211327993.USD","LU0225284248.USD","LU2286300806.USD","LU0476273544.USD","BK4570","LU0070302665.USD","LU0444971666.USD","LU2360106780.USD","FTXL","LU1815333072.USD","SMAX","SPY","IEO","LU2125154935.USD","VDE","XDTE","LU0306807586.USD","SPYM","LU0006061336.USD","LU0300736492.USD","AIS","LU0368265418.SGD","SDS","LU1144417596.USD","SCHB","SPDN","BK4543","TTEQ","LU2089985449.USD","LU1064131342.USD","LU0300736062.USD","DMAX","BK4141","LU0122376428.USD","LU0320765489.SGD","IE00B3CCJ963.GBP","BK4108","LU0061475181.USD","LU1267930813.SGD","VOOG","RSP","LU0187121727.USD","FDX","SOXX","VTI","MOAT","BK4588","LU1894683348.USD","RSPA","WBD","YSPY","IYT","BK4125","SPMO","GNOM","LINT","LU1267930490.SGD","IVW","LU2250418816.HKD","EBAY","NOBL","LU0980610538.SGD","FENY","SH","HK0000304805.HKD","SPYU","LU2264538146.SGD","LU0052756011.USD",".SPX","IE000F7OJYX1.SGD","IJR","BK4602","IE0000B7K699.USD","LU0274383776.USD","HIBS","LU1854103824.USD","LU0154236417.USD","IE00BJJMRX11.SGD","BK4501","LU0314106906.USD","IXC","RSPU","LU1815336760.USD","LU0130103400.USD","SPYG","SPXU","TRUN","LU0788109394.HKD","SPYV","VV","LU0081259029.USD","LU0957808578.USD","QQQA","DOCK","XLE","SPXS","BK4598","LU1571399168.USD","IE00B19Z3B42.SGD","AIQ","BK4524","LU0211331839.USD","LU0130517989.USD","LU0130102774.USD","SFY","LU0496365809.HKD","XNTK","BK4605","ACWI","BK4612","IGE","MRNA","MRNY","LU1852331112.SGD","PSKY","IDNA","LU2125154778.USD","LU2244417387.USD","LU2931357623.SGD","GPIX","TSPY","BK4550","IJH","BK4116","IE00B2Q91V27.USD","LU1430594728.SGD","LU0251142724.SGD","HK0000304797.USD","LU0211326755.USD","SSO","LU0957791311.USD","BK4579","BK4585","IE0002270589.USD","BK4527","XLG","BK4575","SINTCmain","BMAY","LU1894683264.USD","SCHX","BK4608","SPHQ","LU0256863811.USD","LU0306806265.USD","LU1059921491.USD","LU0056508442.USD","LU0211328371.USD","SPYH","LU1854104046.USD","COP","LU0321505439.SGD","LU1712237335.SGD","IE000SO60NU8.SGD","CLIX","LU0321505868.SGD","LU0345780950.USD","LU2148611432.USD","LU0082616367.USD","DBSC","INT","GSLC","TEXU","ALLW","FCG","BK4568","IE000M9KFDE8.USD","IVE","INYY","IE000WAW04H5.SGD","LU0648000940.SGD","LU0719512351.SGD","BK4535","BK4551","LU0238689110.USD","GXPE","LU2357627491.SGD","LU0251131958.USD","AKAM","LU1201861249.SGD","LU1642822529.SGD","BK4170","IYE","LU2133065610.SGD","WLDR","IE00BFSS8Q28.SGD","HULL","WDNA","LU0208291251.USD","LU0648001328.SGD","LU2764263039.SGD","BK4512","LU2237438978.USD","LU0640476718.USD","BK4515","BK4220","SPGP","AKAL","SHPP","LU0211326839.USD","HIBL","IE000MB6IJN5.SGD","LU0859254822.USD","LU0048573561.USD","LU0985481810.HKD","LU1201861165.SGD","SG9999002521.SGD","SPYQ","DRIV","LU0792757196.USD","VBK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669697041","title":"Moderna announces late-breaking data to be presented at ESMO Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669697041","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669697041?lang=en_us&edition=fundamental","pubTime":"2026-09-21 22:15","pubTimestamp":1790000108,"startTime":"0","endTime":"0","summary":"Moderna (MRNA) announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been ac...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderna-announces-late-breaking-data-to-be-presented-at-esmo-congress-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderna-announces-late-breaking-data-to-be-presented-at-esmo-congress-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGHT","BK4533","GNOM","BK4551","IDNA","MRNX","BK4501","BK4568","BK4139","MRNA","BK4585","BK4588","BK4534","BK4548","WDNA","BK4532","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669661341","title":"Avalyn Pharma announces published results from Phase 1 trials of AP02","url":"https://stock-news.laohu8.com/highlight/detail?id=2669661341","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669661341?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:10","pubTimestamp":1789996248,"startTime":"0","endTime":"0","summary":"Avalyn Pharma (AVLN) announced that Respiratory Research has published detailed results from two Phase 1 clinical trials of AP02 in healthy volunte...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-announces-published-results-from-phase-1-trials-of-ap02-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-announces-published-results-from-phase-1-trials-of-ap02-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","GDOC","MEDX","NVIB","BMED","HYLG","BBC","AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669316610","title":"InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669316610","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669316610?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:00","pubTimestamp":1789995600,"startTime":"0","endTime":"0","summary":"- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 - - The amended warrants, if exercised i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/21/3365503/0/en/inspiremd-announces-amendments-to-certain-series-j-and-series-k-warrants-providing-potential-gross-proceeds-of-up-to-11-million.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","IDNA","MRNY","LFSC","PSCH","IEIH","SYNB","MEDI","GNMX","RSPH","MRNX","PINK","NSPR","BMED","BK4585","BBP","BK4588","IBB","NVIB","TBXU","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669315293","title":"Vertex Pharmaceuticals Incorporated : Leerink Partners Resumes Coverage with Outperform Rating; Target Price $594","url":"https://stock-news.laohu8.com/highlight/detail?id=2669315293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669315293?lang=en_us&edition=fundamental","pubTime":"2026-09-21 18:03","pubTimestamp":1789985027,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0009355771.USD","LU2456880835.USD","LU0109394709.USD","LU0061475181.USD","LU2362540622.SGD","LU2462157665.USD","TBXU","BK4567","LU2468319806.SGD","LU1093756325.SGD","LU0320765992.SGD","LU2236285917.USD","LU0058720904.USD","LU2362541273.HKD","LU1093756168.USD","IBBQ","LU1585245621.USD","LU0289739699.SGD","IDNA","PBE","IE00BJJMRZ35.SGD","GNMX","LU0823416689.USD","IE00BZ9MQY76.HKD","BK4139","LU1674673428.USD","LU2324357040.USD","LU2362541513.USD","BIB","LU0234570918.USD","IE00B19Z3581.USD","IE00B4R5TH58.HKD","BK4532","IE00B894F039.SGD","IE00BFTCPJ56.SGD","LU1035775433.USD","IBB","SG9999001176.SGD","BBH","IE00BJT1NW94.SGD","LU0256863811.USD","BK4588","LU1069344957.HKD","LU2417539215.USD","VRTX","LU1778281490.HKD","BK4533","LU2089984988.USD","SG9999013999.USD","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669442151","title":"Ultragenyx price target raised to $35 from $32 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2669442151","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669442151?lang=en_us&edition=fundamental","pubTime":"2026-09-21 17:10","pubTimestamp":1789981807,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Ultragenyx (RARE) to $35 from $32 and keeps an Overweight rating on the shares following FDA approval of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-price-target-raised-to-35-from-32-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","IDNA","TBXU","BMED","BK4588","LABU","PSCH","RSPH","GDOC","BK4139","MRNX","RARE","PINK","SYNB","IBB","MEDI","GNMX","LFSC","TECB","XLVX","MRNY","BK4585","IYH","IEIH","NVIB","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669159507","title":"Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Amneal Pharmaceuticals (AMRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159507","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669159507?lang=en_us&edition=fundamental","pubTime":"2026-09-21 16:20","pubTimestamp":1789978807,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Moderna (MRNA) and Amneal Pharmaceuticals (AMRX). ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-moderna-mrna-and-amneal-pharmaceuticals-amrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-moderna-mrna-and-amneal-pharmaceuticals-amrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","GNOM","BK4534","WDNA","AMRX","BK4585","LU0029874061.USD","MRNY","HCSG","LGHT","BK4501","BK4137","MRNX","BK4548","XBI","BK4533","MRNA","BK4551","BK4007","BK4532","BK4568","IDNA","BK4581","LABU","BK4588","BK4139","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669551271","title":"Incyte Expands Skin Diseases Treatment Partnership in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2669551271","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669551271?lang=en_us&edition=fundamental","pubTime":"2026-09-21 15:52","pubTimestamp":1789977143,"startTime":"0","endTime":"0","summary":"Incyte's  affiliate expanded its partnership with Specialised Therapeutics to commercialize, distribute and register ruxolitinib cream in Australia, Specialised Therapeutics said Sunday.The company said Ruxolitinib cream is approved in Australia to treat non-segmental vitiligo in adults and children ages 12 and older, and mild-to-moderate atopic dermatitis in adults and children ages 2 and older.Under the agreement, Specialised Therapeutics said Incyte will continue to handle development and manufacturing, while it will oversee regulatory submissions, medical affairs, marketing and distribution in Australia.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GEAR.AU","XAO.AU","VAP.AU","BEAR.AU","IMLC.AU","IOZ.AU","VAS.AU","BK4585","QRE.AU","DACE.AU","BK4550","XKO.AU","ZYAU.AU","INCY","IIGF.AU","STW.AU","SLF.AU","EIGA.AU","E200.AU","GIVE.AU","BK4532","BBOZ.AU","IDNA","QFN.AU","IISV.AU","BK4588","OZF.AU","XJO.AU","OZR.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2669412132","title":"Correction to Vertex Material Listing Article on Sept. 17","url":"https://stock-news.laohu8.com/highlight/detail?id=2669412132","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669412132?lang=en_us&edition=fundamental","pubTime":"2026-09-21 12:48","pubTimestamp":1789966080,"startTime":"0","endTime":"0","summary":"Tan Chin Teong is the founder and technical director of Vertex Material. \"Malaysia's Vertex Material Sets Sights on 2027 U.S. Listing,\" at 0931 GMT on Sept. 17, misstated the name as Tan Chin Tong.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","LU0823416689.USD","IE00B19Z9Z06.USD","SGXZ57979304.SGD","IDNA","LU0889565916.HKD","TBXU","BK4588","LU2362541513.USD","LU1035775433.USD","LU2462157665.USD","LU0079474960.USD","LU0256863811.USD","LU1778281490.HKD","VRTX","LU1093756168.USD","PBE","IE00B19Z3B42.SGD","BK4567","LU2324357040.USD","SG9999001176.USD","SG9999013999.USD","IE00B19Z9P08.USD","LU0417517546.SGD","LU0566484027.USD","IE00BFTCPJ56.SGD","LU2236285917.USD","SG9999001176.SGD","LU2362540622.SGD","LU0234570918.USD","LU1585245621.USD","IBB","LU2089984988.USD","BIB","LU0058720904.USD","LU1069344957.HKD","GNMX","LU0320765992.SGD","IBBQ","BK4023","VERX","LU2468319806.SGD","LU2362541273.HKD","LU0109394709.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU1093756325.SGD","IE00BJJMRZ35.SGD","IE00B894F039.SGD","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669230180","title":"Specialised Therapeutics expands partnership with Incyte to include Opzelura","url":"https://stock-news.laohu8.com/highlight/detail?id=2669230180","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669230180?lang=en_us&edition=fundamental","pubTime":"2026-09-21 06:25","pubTimestamp":1789943112,"startTime":"0","endTime":"0","summary":"Independent biopharmaceutical company Specialised Therapeutics announced an expansion of its existing partnership with Incyte (INCY) Biosciences In...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/specialised-therapeutics-expands-partnership-with-incyte-to-include-opzelura-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/specialised-therapeutics-expands-partnership-with-incyte-to-include-opzelura-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BK4550","IDNA","BK4588","LENZ","BK4585","BK4539","BK4532","INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668318487","title":"Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2668318487","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668318487?lang=en_us&edition=fundamental","pubTime":"2026-09-20 22:15","pubTimestamp":1789913705,"startTime":"0","endTime":"0","summary":"Cue Biopharma (CUE) announced positive topline results from the Phase 2 clinical trial of CUE-221 conducted in China by Genesis Life Sciences, a re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cue-biopharma-announces-phase-2-trial-of-cue-221-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cue-biopharma-announces-phase-2-trial-of-cue-221-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","BBC","CUE","NVIB","PSIL","HYLG","MEDX","BK4139","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668186624","title":"Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2668186624","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668186624?lang=en_us&edition=fundamental","pubTime":"2026-09-20 18:00","pubTimestamp":1789898400,"startTime":"0","endTime":"0","summary":"Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling studyPrimary endpoint and the key secondary e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/20/3365072/0/en/cue-biopharma-announces-positive-topline-results-from-cue-221-phase-2-study-in-chronic-spontaneous-urticaria.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","IDNA","HYLG","NVIB","MEDX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}